Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670524 | 0.90 | CYP11B2 (0.39) | HTR2CHTR2AHTR2BSCN10ACYP11B2 | |
| SCHEMBL19670692 | 0.85 | BRAF (0.38) | HTR2CHTR2AHTR2BTRPV3CYP1A2 | |
| SCHEMBL19670565 | 0.82 | WNT3A (0.37) | HTR2CHTR2AHTR2BCYP11B2CYP1A2 | |
| SCHEMBL19365749 | 0.78 | CA2 (0.42) | — | |
| SCHEMBL19699072 | 0.77 | DYRK1A (0.35) | HTR2CHTR2AHTR2BCYP11B2TRPV3 | |
| SCHEMBL19699071 | 0.77 | HTR2C (0.47) | HTR2CHTR2AHTR2B | |
| SCHEMBL19670640 | 0.77 | HTR2C (0.51) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL19670249 | 0.76 | CA2 (0.42) | HTR2CHTR2A | |
| SCHEMBL19670453 | 0.76 | HTR2C (0.36) | HTR2CHTR2AHTR2BTRPV3CYP1A2 | |
| SCHEMBL17618636 | 0.75 | SCN10A (0.39) | HTR2CHTR2AHTR2BSCN10ATRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR2C 4651/4885HTR2A 4386/4885HTR2B 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.